{
    "id": 30140,
    "fullName": "B2M loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "B2M loss indicates loss of the B2M gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 567,
        "geneSymbol": "B2M",
        "terms": [
            "B2M",
            "IMD43"
        ]
    },
    "variant": "loss",
    "createDate": "05/13/2019",
    "updateDate": "05/13/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16943,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, melanoma patients with B2M loss of heterozygosity were threefold less likely to respond to Keytruda (pembrolizumab) treatment, as compared to patients without loss of B2M (PMID: 29070816).",
            "molecularProfile": {
                "id": 32261,
                "profileName": "B2M loss"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11969,
                    "pubMedId": 29070816,
                    "title": "Resistance to checkpoint blockade therapy through inactivation of antigen presentation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29070816"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16942,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, melanoma patients with B2M loss of heterozygosity were threefold less likely to respond to Yervoy (ipilimumab) treatment, as compared to patients without loss of B2M (PMID: 29070816).",
            "molecularProfile": {
                "id": 32261,
                "profileName": "B2M loss"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11969,
                    "pubMedId": 29070816,
                    "title": "Resistance to checkpoint blockade therapy through inactivation of antigen presentation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29070816"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32261,
            "profileName": "B2M loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}